Author Archives: ev1

Nanomedicine characterization at NCI’s Nanotechnology Characterization Lab (NCL) – Video

Posted on by


Nanomedicine characterization at NCI #39;s Nanotechnology Characterization Lab (NCL)
Speaker: Dr. Scott E. McNeil, Director, Nanotechnology Characterization Laboratory, National Cancer Institute (USA) CLINAM 7/ 2014, 7th Conference and Exhibi...

By: TAUVOD

Go here to see the original:
Nanomedicine characterization at NCI's Nanotechnology Characterization Lab (NCL) - Video

Nanomedicine with Sustained Efficacy in Oncology in Late-stage Preclinical Development – Video

Posted on by


Nanomedicine with Sustained Efficacy in Oncology in Late-stage Preclinical Development
Speaker: Dr. Cristianne JF Rijcken, PharmD, CEO, Cristal Delivery B.V., Maastricht (NL) CLINAM 7/ 2014, 7th Conference and Exhibition, June 23-25, 2014.

By: TAUVOD

Go here to see the original:
Nanomedicine with Sustained Efficacy in Oncology in Late-stage Preclinical Development - Video

Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com

Posted on by

London, UK (PRWEB) March 05, 2015

The emergence of nanotechnology has greatly impacted the clinical therapeutics landscape over the past decade. The pharmaceutical world has witnessed advancements in biocompatible nanoscale carriers for drug delivery in the form of liposomes and polymeric nanoparticles that are capable of delivering manifold drugs with more safety and efficiency. In the area of cancer therapeutics, the nanoparticles could perhaps rely greatly upon the enhanced permeability and retention (EPR) effect induced by leaky tumour vasculatures for a better accumulation of drugs at the tumour sites. Due to these benefits, the therapeutic nanoparticles in this respect have grown into a very promising field with the potential to successfully take the place of traditional chemotherapy.

The development of nanoparticle drug delivery systems for the treatment of cancer is set to become a lucrative field in the years to come. The protein polymers from natural sources emerge as up-and-coming materials for building the nanocarrier systems. The commercial success of albumin-based nanoparticles has also generated great interest in other proteins. With the rational design of protein nanoparticles on the grounds of their behaviours in the tumour microenvironment and based on the cell biology of cancer, enhanced cancer treatment efficacy and safety can be achieved.

Topical report Cancer Nanomedicine Market & Pipeline Insight 2015 worked out by Kuick Research is now available at MarketPublishers.com.

Report Details:

Title: Cancer Nanomedicine Market & Pipeline Insight 2015 Published: February, 2015 Pages: 220 Price: US$ 2,000.00 http://marketpublishers.com/report/diagnostics-diseases/cancer/cancer-nanomedicine-market-pipeline-insight-2015.html

The report offers an essential guide to the worldwide cancer nanomedicine marketplace. It provides deep insights into the role of nanomedicine in cancer therapies, contains a detailed classification of cancer nanoparticles drug delivery systems, looks at the mechanism of tumour nanomedicine treatment. The study presents a deep overview of the cancer nanomedicine clinical development pipeline, looking at it based on indication, stage and company. It reviews the 79 candidates in clinical development, the 8 marketed cancer nanomedicine drugs. The competitive landscape is canvassed as well including a discussion of the 11 leading companies. The report casts light on the market dynamics covering key drivers and commercialisation challenges, besides speculating on the future prospects of the market.

Companies reviewed comprise: Abraxis BioScience, Alnylam Pharmaceuticals, Access Pharmaceuticals, Bind Biosciences, Samyang, Arrowhead Research, Epeius Biotechnologies, Nanobiotix, Nippon Kayaku, NanoCarrier, and Takeda Pharmaceutical.

Report Highlights:

More topical studies by the publisher can be found at Kuick Research page.

The rest is here:
Cancer Nanomedicine Marketplace Discussed by Kuick Research in Topical Study Recently Published at MarketPublishers.com

Rahmberg-Walsh joins school board

Posted on by

FITCHBURG -- The newest member of the School Committee is Elizabeth Rahmberg-Walsh, a behavioral-science professor in Fitchburg State University's criminal-justice program.

At a joint meeting of the School Committee and City Council on Tuesday night, Rahmberg-Walsh was appointed by a 14-3 vote.

Rahmberg-Walsh, a Boutelle Street resident, was one of two candidates who submitted their names for the appointment. The other is longtime Fitchburg resident Kelly Johnson, a Charles Street resident.

The position became open in January when School Committee member Nick Carbone resigned because he had moved out of the city.

Rahmberg-Walsh was at a criminal-justice science conference Tuesday night and was not able to attend the meeting, but prepared a video presentation that was played on her behalf. In the video, she said she is concerned about students graduating from high school unprepared for college.

"We cannot wait until students are in high school to begin those lessons," she said.

Rahmberg-Walsh also serves as co-director of FSU's dating-violence prevention program.

Johnson said she was not necessarily the best candidate for the position, but submitted her name for consideration to give the voting members a choice.

Johnson has a son in middle school who went through South Street Elementary, but she has since moved him to a private school. She said she did so because of concerns of him being bullied while walking to the middle school, and identified bullying as the top issue she wished to focus on.

The three members who voted for Johnson are City Councilor Joel Kaddy, School Committee member Pete Stephens and Mayor Lisa Wong, who chairs the School Committee.

See more here:
Rahmberg-Walsh joins school board